MeMed For Profit
The immune system is built to communicate. Our mission is to listen. We apply machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights. MeMed�s machine learning-based diagnostics address key clinical and medical challenges in infectious diseases and inflammatory disorders. MeMed BV Bacterial and viral infections are often clinically indistinguishable
Investors
Connections from
Founded Date:
2009
Number Of Exists:
N/A
Investment Stage:
N/A
Industry:
Biomarkers of Longevity
Estimated Revenue:
$26 Million
Headquarters:
Tirat Carmel, Hefa, Israel
Technology:
Biomarker panels
Investor Type:
N/A
Employee Number:
101-250
Funding Status:
Late Stage Venture